Match coverage to the exact medicine and use.

Approval to treat is not a promise to pay

Under the September 26, 2026 rules, Medicare drug plans may pay for a medicine when it treats a qualifying health problem other than weight loss. Examples include an approved use for type 2 diabetes or for reducing certain heart risks.

The plan still checks its list of medicines it pays for and may require payment approval in advance. A doctor recommending the medicine, or the FDA approving that use, does not guarantee the plan will pay.

Prior authorization means seeking payment approval before coverage begins.

Ask about Medicare’s temporary payment program

Tirzepatide, sold as Mounjaro and Zepbound, is a medicine used for blood sugar or weight care. The two brands have different approved uses.

Your body makes a hormone called GLP-1. A hormone carries messages; this one helps manage appetite and blood sugar. Tirzepatide is among the medicines that copy its action.

Medicare calls its temporary program the GLP-1 Bridge. It helps eligible people pay for certain weight-loss medicines, with both pills and shots included. The monthly payment was $50 on September 26, 2026.

Its opening date was July 1, 2026, with an end date set for December 31, 2027.

Among tirzepatide (Zepbound) packages, only the KwikPen is included in the Bridge. That is an injection pen holding several doses. Small medicine bottles, called vials, and pens holding a single dose are excluded.

It operates outside Medicare’s usual drug benefit, called Part D.

The Bridge payment does not count toward the yearly Part D cap on what you pay yourself.

Check the health and insurance requirements

The health and plan rules below were recorded September 26, 2026. Adults aged 18 or older may qualify. The program looks at their health when treatment began.

BMI is a score worked out from your height and weight. Ask your clinician to calculate it and check which of these groups fits your records.

At BMI 35 or above, the weight requirement is met without one of the extra conditions below.

At BMI 30 or above, one route is high blood pressure despite treatment with two medicines for it. The qualifying reading is over 140 for the upper number or over 90 mm Hg for the lower number.

BMI 30 or above also has two other possible routes. One is chronic kidney disease, meaning long-term kidney disease, recorded as stage 3a or a later stage. The other is a type of heart failure with a normal squeeze, called “preserved ejection fraction.” Have your clinician check the recorded type or stage.

At BMI 27 or above, the extra condition can be pre-diabetes: blood sugar above normal but below diabetes. A previous heart attack or stroke also qualifies as the extra condition, as does artery disease causing symptoms in the limbs.

Check the plan requirement too. One accepted option is a separate Part D drug plan. Another is a Medicare Advantage plan with coordinated care and drug coverage. Other plan types may require you to hold a separate Part D plan; ask your insurer which category applies.

For a person who has type 2 diabetes, payment goes through the usual Part D process; the Bridge is not available. Obstructive sleep apnea blocks Bridge access when moderate or severe; blocked airflow repeatedly interrupts your breathing while you sleep. Another exclusion is MASH, a form of liver inflammation linked to fat, when there is moderate to advanced scarring and no cirrhosis (the most advanced scarring). These conditions go to the usual Part D coverage process.

For a prescription aimed at reducing major heart and stroke risks, the request belongs with the Part D plan too.

If Part D already paid for a GLP-1 medicine for you in 2026, the Bridge is not available to you in 2026. The record did not yet set the corresponding rule for 2027.

A prescriber must also provide a prescription and seek payment approval in advance. Treatment must go alongside an ongoing program of structured nutrition and physical activity, meaning planned eating and exercise.

Get the answer for your own plan

Ask which document confirms coverage and what happens after a denial. Ask whether a new approval is needed later.

If the answer is unclear, keep that question open on the worksheet. A quote and a coverage decision belong beside each other.